SciClone dumps cancer drug after failed IIb

Foster City, CA-based SciClone Pharmaceuticals ($SCLN) has come up empty-handed again after concluding its latest Phase IIb trial for SCV-07 should be shuttered after proving ineffective for oral mucositis, a common side effect for cancer patients. Investigators earlier tried and failed to demonstrate the treatment might be effective for hepatitis C. SciClone said on Friday it is washing its hands of the drug as it shifts all of its focus to China's specialty drug market. Release
 

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.